Quantbot Technologies LP Buys Shares of 33,000 Bristol Myers Squibb Company $BMY

Quantbot Technologies LP purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, HoldingsChannel.com reports. The fund purchased 33,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,901,000.

Other hedge funds have also recently made changes to their positions in the company. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. raised its stake in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the last quarter. Bayban bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 4th quarter worth $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

BMY opened at $67.30 on Tuesday. The company has a 50 day simple moving average of $60.77 and a two-hundred day simple moving average of $59.47. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a market cap of $137.47 billion, a P/E ratio of 14.82, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Wall Street Analyst Weigh In

Several brokerages recently commented on BMY. Roth Capital initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price objective for the company. Raymond James Financial assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the company an “equal weight” rating in a research note on Friday, July 31st. Truist Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.